Skip to Content
Merck
All Photos(1)

Documents

SAB4301339

Sigma-Aldrich

Anti-phospho-4E-BP1 (pThr70) antibody produced in rabbit

affinity isolated antibody

Synonym(s):

4EBP1, P/OKCL.6, PHAS-I

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

Quality Level

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

12 kDa

species reactivity

human

concentration

1.0 mg/mL

technique(s)

immunohistochemistry: 1:50-1:100

isotype

IgG

accession no.

NP_004086.1.

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

phosphorylation (pThr70)

Gene Information

human ... EIF4EBP1(1978)

General description

The gene EIF4EBP1 (eukaryotic translation initiation factor 4E binding protein 1) is localized on human chromosome 8p12. It is a translation repressor that interacts with eukaryotic translation initiation factor 4E (eIF4E).

Specificity

The antibody detects endogenous levels of 4E-BP1 only when phosphorylated at threonine 70.

Immunogen

Peptide sequence around phosphorylation site of threonine70 (T-K-T(p)-P-P) derived from Human 4E-BP1.

Biochem/physiol Actions

EIF4EBP1 (eukaryotic translation initiation factor 4E binding protein 1) associates with eukaryotic translation initiation factor 4E (eIF4E), which is a multisubunit complex that recruits 40S ribosomal subunits to the 5′ end of mRNA. The interaction of the encoded binding protein with this complex inhibits translation. The phosphorylation of EIF4EBP1 in response to stimuli such as, UV irradiation and insulin signaling, results in dissociation of this factor from the eIF4E complex, leading to initiation of translation of mRNA. This protein participates in cell proliferation, apoptosis, invasion and metastasis. EIF4EBP1 functions as an effector molecule in mTOR (mammalian target of rapamycin complex 1) signaling pathway that regulates protein synthesis. It is found to be overexpressed in hepatocellular carcinoma tissues and serves as a potential prognostic and therapeutic target.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

EIF4EBP1 overexpression is associated with poor survival and disease progression in patients with hepatocellular carcinoma.
Cha YL, et al.
PLoS ONE, 10(2), e0117493-e0117493 (2015)
High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.
Boylan MO, et al.
Breast Cancer Research, 272(28), 17438-17443 (1997)
Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism.
Gingras AC, et al.
Genes & Development, 13(11), 1422-1437 (1999)
eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer.
Chao MW, et al.
Oncotarget, 6(27), 24092-24104 (2015)
Hui-Ying Huang et al.
Translational cancer research, 11(5), 1076-1088 (2022-06-17)
New and effective chemotherapy or targeted therapy strategies are needed against laryngeal squamous cell carcinoma (LSCC). We aimed to explore the antitumor effect of dual PI3K/mTOR inhibitor combined with autophagy suppression on LSCC and its underlying mechanism. Hep-2 and AMC-HN-8

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service